Visit DARZALEX® (daratumumab) for more information about this drug’s original formulation and its intravenous administration. 

What is Darzalex Faspro?

Darzalex Faspro®, a combination of Darzalex and hyaluronidase (an endoglycosidase), is a formulation given as an abdominal injection under the skin (subcutaneous, SQ) that has been determined to be as effective as the original formulation of Darzalex. Switching from IV to SQ must first be discussed with your doctor.

Who is a candidate for Darzalex Faspro?

Darzalex Faspro is used in myeloma as part of the following treatments:

  • In newly diagnosed patients who are ineligible for ASCT, in combination with Rd or VMP. 
  • In patients who have received at least 1 prior therapy, in combination with Vd. 
  • As monotherapy in patients who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who are double-refractory to a proteasome inhibitor and an immunomodulatory drug. 

How is Darzalex Faspro given?

Darzalex Faspro is given by a healthcare professional as an abdominal SQ injection that takes only a few minutes. The dose is 1,800 mg daratumumab plus 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) solution in a single-dose vial.

What are the possible adverse events to Darzalex Faspro?

The most common hematological abnormalities in laboratory tests (≥40%) with Darzalex Faspro are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin. Your doctor will monitor your blood counts.

What are the most common side effects with Darzalex Faspro?

The most common side effects (≥ 20%) with Darzalex Faspro are:

  • With monotherapy: Upper respiratory tract infection. 
  • With combination therapy: Fatigue, nausea, diarrhea, shortness of breath, trouble sleeping, fever, cough, muscle spasms, back pain, vomiting, cold-like symptoms (upper respiratory tract infection), peripheral neuropathy (nerve damage causing tingling, numbness, or pain), constipation, and lung infection (pneumonia). 

Special precautions with Darzalex Faspro

  • Hypersensitivity: Your doctor will discontinue Darzalex Faspro for life-threatening reactions. 
  • Neutropenia: Your doctor will monitor your complete blood cell counts during treatment, and monitor for signs of infection. 
  • Thrombocytopenia: Your doctor will monitor your complete blood cell counts during treatment. 
  • Embryo-fetal toxicity: Darzalex Faspro can cause fetal harm. Females of reproductive potential should use effective contraception.
  • Interference with cross-matching and red blood cell antibody screening: Your doctor will screen you prior to starting treatment. Blood banks should be informed that you have received Darzalex Faspro. 

Janssen CarePath Program

Please call 1-844-553-2792 or visit the Janssen CarePath Program website for more information.


Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.